Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HYPD NASDAQ:KLDO NASDAQ:PHXM NASDAQ:SELB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYPDHyperion DeFi$7.08-14.3%$8.15$0.85▼$93.60$39.67M2.42914,650 shs376,612 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.07$4K-0.0612,338 shs1,222 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASELBSelecta Biosciences$1.06$0.81▼$1.99$136.76M0.84979,585 shs2.77 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYPDHyperion DeFi0.00%-8.05%-55.64%+505.13%-92.92%KLDOKaleido Biosciences0.00%0.00%0.00%-95.00%0.00%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SELBSelecta Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHYPDHyperion DeFi0.3604 of 5 stars1.00.00.00.02.20.80.6KLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASELBSelecta Biosciences1.0969 of 5 stars0.00.00.04.50.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHYPDHyperion DeFi 2.00Hold$2.00-71.75% DownsideKLDOKaleido Biosciences 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ASELBSelecta Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHYPDHyperion DeFi$60K660.80N/AN/A($695.52) per share-0.01KLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ASELBSelecta Biosciences$110.78M0.00N/A9.91$0.61 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)KLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ASELBSelecta Biosciences$35.38M-$0.22N/AN/AN/A-72.04%-44.13%-22.00%N/ALatest SELB, HYPD, PHXM, and KLDO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHYPDHyperion DeFiN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ASELBSelecta BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHYPDHyperion DeFiN/A0.340.34KLDOKaleido BiosciencesN/AN/AN/APHXMPHAXIAM Therapeutics0.231.78N/ASELBSelecta Biosciences0.214.184.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHYPDHyperion DeFi25.84%KLDOKaleido Biosciences81.56%PHXMPHAXIAM Therapeutics0.40%SELBSelecta Biosciences41.95%Insider OwnershipCompanyInsider OwnershipHYPDHyperion DeFi10.86%KLDOKaleido Biosciences9.00%PHXMPHAXIAM Therapeutics1.94%SELBSelecta Biosciences31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHYPDHyperion DeFi405.60 million5.00 millionOptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataSELBSelecta Biosciences64155.20 million106.78 millionOptionableSELB, HYPD, PHXM, and KLDO HeadlinesRecent News About These Companies2025 Poinsettias catalog available from Selecta OneJanuary 31, 2025 | nurserymag.comN2025 Poinsettias catalog available now from Selecta OneJanuary 29, 2025 | greenhousemag.comGLeigh Francis insists Bo Selecta! reboot will never happenOctober 20, 2024 | msn.comLISTEN: Firebeatz and Noise Cans Join Forces in “Selecta”September 25, 2024 | runthetrap.comRLeigh Francis in Leeds: Keith Lemon and Bo Selecta! star announces evening of laughter at Leeds Grand TheatreSeptember 23, 2024 | msn.comLeigh Francis interview: Leeds comedian of Keith Lemon and Bo' Selecta! fame on his fear of being cancelledSeptember 20, 2024 | msn.comAstellas licenses companion drug for Pompe gene therapySeptember 8, 2024 | pharmaphorum.comPCraig David spoke out on how Bo Selecta 'ruined his life'May 15, 2024 | ladbible.comLCraig David says Bo Selecta ‘ruined his life’May 14, 2024 | joe.co.ukJLeigh Francis says Bo Selecta couldn’t be made today because ‘you’ve got to be mindful nowadays’May 12, 2024 | joe.co.ukJCraig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'May 6, 2024 | msn.comSelecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressantsMarch 12, 2024 | pharmaceutical-technology.comPSelb, Germany - Weather Forecasts | Maps | News - Yahoo WeatherJanuary 23, 2024 | yahoo.comNanotechnology in Massachusetts – companies, research, and degree programsJanuary 13, 2024 | nanowerk.comNCartesian Therapeutics Inc (RNAC)December 15, 2023 | investing.comSelecta Biosciences, Cartesian Therapeutics Merge to Create Public RNA Cell Therapy FirmNovember 14, 2023 | precisionmedicineonline.comPFurther weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%November 14, 2023 | finance.yahoo.comPared-down Selecta merges with Maryland biotechNovember 13, 2023 | bizjournals.comSelecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell TherapyNovember 13, 2023 | msn.comSelecta Biosciences Merges With Cartesian Therapeutics In All-stock DealNovember 13, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSELB, HYPD, PHXM, and KLDO Company DescriptionsHyperion DeFi NASDAQ:HYPD$7.08 -1.18 (-14.29%) As of 08/1/2025 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Kaleido Biosciences NASDAQ:KLDO$0.0001 0.00 (0.00%) As of 08/1/2025 09:34 AM EasternKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 08/1/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Selecta Biosciences NASDAQ:SELBSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
